As the Irvine, CA-based company strengthens its mitral valve portfolio, it also faces a lawsuit from Abbott Laboratories over the Pascal system.
Think your startup has what it takes to go head to head with other young companies in medtech? Find out by entering our annual tournament.
The company said it will sell its health information systems business unit to Philips. The deal is expected to close later this year.
Parsippany-Troy Hills, NJ-based Pacira Pharmaceuticals to pay up to $120 million cash up front and an additional $100 million upon the achievement of milestones under the terms of the deal.
The company said the pause in sales was temporary and that it was not related to the performance and safety of Recell.
Influenza and its complications cause as many as 140,000 to 710,000 hospitalizations and 12,000 to 56,000 deaths annually in the U.S.
General Electric announced earlier this week that it would sell its pharmaceutical unit to Danaher for about $21 billion.
The Dublin-based company received approval for an expanded chronic total occlusion indication for its Resolute DES platform.
CEO John Onopchenko said the company is shifting from a defensive position to an offensive position and expects to return to growth in the second half of the year.
The Lake Oswego, OR-based company has received a nod from FDA for the Orsiro stent which it said outperformed Abbott’s Xience stent in a clinical study.
The diabetes devices market is more competitive than ever before. Here's what we expect to see this year from the leading players in the space.
Mauna Kea said it decided to terminate an agreement with Cook Medical due to a lack of commercial progress. The deal included the development of a private-label version of the Cellvizio confocal laser endomicroscopy system for urologic applications.